Cipher Pharmaceuticals Inc. (TSX:CPH)

Cipher Pharmaceuticals Ratios and Metrics

Market cap in millions CAD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 21, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Cap	430	382	367	133	96	46
Market Cap Growth	19.59%	4.19%	175.95%	38.04%	109.70%	83.10%
Enterprise Value	421.27	378.85	398.85	80.43	57.56	20.51
Last Close Price	16.90	15.06	14.32	5.54	3.84	1.77
PE Ratio	10.16	10.45	21.70	5.23	2.75	4.83
Forward PE	13.39	18.41	15.93	11.11	8.77	3.95
PS Ratio	6.04	5.52	7.66	4.74	3.43	1.65
PB Ratio	2.32	2.20	2.50	1.25	1.11	0.93
P/TBV Ratio	3.34	3.09	3.53	1.75	1.61	1.22
P/FCF Ratio	10.26	-	13.10	6.28	6.66	2.63
P/OCF Ratio	10.25	-	13.07	6.27	6.61	2.63
EV/Sales Ratio	5.92	5.47	8.33	2.87	2.05	0.74
EV/EBITDA Ratio	11.05	16.72	30.37	5.39	3.52	1.30
EV/EBIT Ratio	15.00	16.72	54.15	6.05	3.84	1.37
EV/FCF Ratio	10.06	-	14.25	3.80	3.99	1.17
Debt / Equity Ratio	0.00	0.04	0.39	0.00	0.01	0.01
Debt / EBITDA Ratio	0.02	0.33	4.43	0.03	0.04	0.04
Debt / FCF Ratio	-	-	2.08	0.02	0.04	0.04
Net Debt / Equity Ratio	-0.04	-0.02	0.22	-0.49	-0.44	-0.51
Net Debt / EBITDA Ratio	-0.30	-0.12	2.49	-3.51	-2.36	-1.60
Net Debt / FCF Ratio	-	-	1.17	-2.47	-2.67	-1.45
Asset Turnover	0.33	0.32	0.27	0.26	0.33	0.46
Inventory Turnover	1.14	1.43	2.11	1.59	2.10	2.90
Quick Ratio	0.79	0.75	1.59	8.55	3.80	2.21
Current Ratio	1.25	1.12	1.94	9.19	4.07	2.39
Return on Equity (ROE)	23.84%	23.80%	12.63%	28.19%	51.73%	21.69%
Return on Assets (ROA)	19.53%	16.53%	16.14%	20.18%	40.89%	17.27%
Return on Invested Capital (ROIC)	21.38%	18.74%	22.23%	39.12%	77.25%	30.77%
Return on Capital Employed (ROCE)	14.99%	12.05%	4.59%	13.82%	21.30%	32.04%
Earnings Yield	10.03%	9.57%	4.61%	19.14%	36.40%	20.71%
FCF Yield	9.75%	0.00%	7.63%	15.93%	15.01%	38.04%
Buyback Yield / Dilution	-0.65%	-2.70%	0.79%	5.25%	0.00%	1.96%
Total Shareholder Return	-0.65%	-2.70%	0.79%	5.25%	0.00%	1.96%

Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.